Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer

Background: The combination of immune checkpoint inhibitors (ICIs) and chemotherapy (CT) is a new strategy to explore cancer treatment in recent years, and it is also practiced in triple-negative breast cancer (TNBC). However, several published randomized controlled trials (RCTs) reported heterogene...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Yihang, Zhang, Wenxiang, Jiang, Ray, Xu, Olivia, Kong, Xiangyi, Zhang, Lin, Fang, Yi, Wang, Jingping, Wang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523473/
https://www.ncbi.nlm.nih.gov/pubmed/36188589
http://dx.doi.org/10.3389/fphar.2022.960323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523473/
https://www.ncbi.nlm.nih.gov/pubmed/36188589
http://dx.doi.org/10.3389/fphar.2022.960323

Ejemplares similares